Бронхиальная астма, ассоциированная с Chlamydophila pneumoniae-инфекцией | КМАХ

Бронхиальная астма, ассоциированная с Chlamydophila pneumoniae-инфекцией

Клиническая Микробиология и Антимикробная Химиотерапия. 2007; 9(3):233-243

​ Белоцерковская Ю.Г., Казаков С.П., Синопальников А.И.
бронхиальная астма Chlamydophila pneumoniae макролиды азитромицин
Раздел
Болезни и возбудители
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2007; 9(3):233-243

Аннотация

В открытом рандомизированном сравнительном исследовании эффективности 8-недельной терапии азитромицином участвовал 71 пациент с нетяжёлой стабильной бронхиальной астмой. Диагностика хронической инфекции, вызванной Chlamydophila pneumoniae, осуществлялась серологическими методами. Затем пациенты распределялись в 4 группы: 2 лечебные (серопозитивная и серонегативная) и 2 группы контроля (серопозитивная и серонегативная). В определённые временные точки (до и после лечения; через 4 и 16 нед после окончания лечения) у пациентов оценивались дневные и ночные симптомы, ОФВ1, утренняя ПСВ и частота использования вентолина по требованию. По окончании лечения было выявлено достоверное улучшение ОФВ1 и ПСВ только в группе серопозитивных пациентов. В то же время не было выявлено достоверного изменения дневных и ночных симптомов и частоты приёма вентолина. По результатам исследования был сделан вывод о том, что лёгкое течение заболевания в меньшей степени ассоциируется с феноменом серопозитивности (IgA + IgG), нежели среднетяжёлое, а терапия азитромицином может быть эффективной только у пациентов с подтверждённой инфекцией.

  • 1. Глобальная стратегия лечения и профилактики бронхиальной астмы / Под ред. Чучалина А.Г. М.: Изд. дом «Атмосфера»; 2007. 104 с.
  • 2. Biscione G.L., Corne J., Chauhan A.J., et al. Increased frequency of detection of Chlamydophila pneumoniae in asthma. Eur Respir J 2004; 24:745-9.
  • 3. Hahn D.L., McDonald R. Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma? Ann Allergy Asthma Immunol 1998; 81:339-44.
  • 4. Esposito S., Principi N. Asthma in children: are chlamydia or mycoplasma involved? Paediatr Drugs 2001; 3:159-68.
  • 5. Blasi F., Cosentini R., Tarsia P., Capone P., Allegra L. Atypical pathogens and asthma: can they influence the natural history of the disease? Monaldi Arch Chest Dis 2001; 56:276-80.
  • 6. Daian C.M., Wolff A.H., Bielory L. The role of atypical organisms in asthma. Allergy Asthma Proc 2000; 21:107- 11.
  • 7. Hahn D.L., Dodge R.W., Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 1991; 266:225-30.
  • 8. Von Hertzen L., Toyryla M., Gimishanov A., et al. Asthma, atopy and Chlamydia pneumoniae antibodies in adults. Clin Exp Allergy. 1999; 29:522-28.
  • 9. Hahn D.L. Chlamydia pneumoniae, asthma and COPD: What is the evidence? Ann Allergy Asthma Immunol 1999; 83:271-88.
  • 10. Von Hertzen L., Vasankari T., Liippo K., et al. Chlamydia pneumoniae and severity of asthma. Scand J Infect Dis 2002; 34:22-7.
  • 11. Black P.N., Scicchitano R., Jenkins C.R. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000; 15:254-9.
  • 12. Isaacs D., Joshi P. Respiratory infections and asthma. Med J Aust 2002;177(Suppl):S50-51.
  • 13. Allegra L., Blasi F., Centanni S. et al. Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection. Eur Respir J. 1994; 7:2165-8.
  • 14. Miyashita N., Kubota Y., Nakajima M. et al. Chlamydia pneumoniae and exacerbations of asthma in adults. Ann Allergy Asthma Immunol. 1998; 80:405-9.
  • 15. Cunningham A.F., Johnston S.L., Julious S.A., et al. Chronic Chlamydia pneumoniae infection and asthma exacerbations in children. Eur Respir J 1998; 11:345-9.
  • 16. Von Hertzen L.C. Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J 2002; 19: 546-56.
  • 17. Ward M.E. The immunobiology and immunopathology of chlamydial infections. APMIS 1995; 103:769-96.
  • 18. Kuo C.C., Jackson L.A., Campbell L.A., Grayston J.T. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev1995; 8:451-61.
  • 19. Beatty W.L., Morrison R.P., Byrne G. Persistent Chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58:686-99.
  • 20. Yang Z., Cummings P.K., Patton D.L., Kuo C. Ultrastructural lung pathology of experimental Chlamydia pneumoniae pneumonitis in mice. J Infect Dis 1994; 170:464-7.
  • 21. Gaydos G.A., Summersgill J.T., Sahany N.N., et al. Repli­cation of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64:1614-20.
  • 22. Kaukoranta-Tolvanen S.S., Laitinen K., Saikku P., Leinonen M. Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog 1994; 16:313-9.
  • 23. Kaukoranta-Tolvanen S.S., Teppo A.M., Laitinen K., et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996; 21:215-21.
  • 24. Airenne S., Surcel H.M., Alakarppa H., et al. Chlamydia pneumoniae infection in human monocytes. Infect Immun 1999; 67:1445-9.
  • 25. Redecke V., Dalhoff K., Bohnet S., et al. Interaction of Chlamydia pneumoniae and humanalveolar macrophages: infection and inflammatory response. Am J Respir Cell Mol Biol 1998; 19:721-7.
  • 26. Shemer-Avni Y., Lieberman D. Chlamydia pneumoniae induced ciliostasis in ciliated bronchial epithelial cells. Infect Dis 1995; 171: 1274-8.
  • 27. Yang J., Hooper W.C., Phillips D.J., et al. Induction of proinflammatory cytokines in human lung epithelial cells during Chlamydia pneumoniae infection. Infect Immun 2003; 71:614-20.
  • 28. Halme S., Latvala J., Karttunen R., et al. Cell-mediated innune response during primary Chlamydia pneumoniae infection. Infect. Immun 2000; 68:7156-8.
  • 29. Koh W.P., Taylor M.B., Hughes K., et al. Seroprevalence of IgG antibodies against Chlamydia pneumoniae in Chinese, Malays and Asian Indians in Singapore. Int J Epidemiol 2002; 31:1001-7.
  • 30. Ferrari M., Poli A., Olivieri M., et al. Seroprevalence of Chlamydia pneumoniae antibodies in a young adult population sample living in Verona. European Community Respiratory Health Survey (ECRHS) Verona. Infection 2000; 28:38-41.
  • 31. Leowattana W., Mahanonda N., Bhuripanyo K., et al. Seroprevalence of Chlamydia pneumoniae infection in Thailand. J med Assoc Thai 2000; 83(Suppl 2):S1-S5.
  • 32. Blasi F., Tarsia P., Arosio C., et al. Epidemiology of Chlamydia pneumoniae. Clin Microbiol Infect 1998; 4 (Suppl 4):S1-S6.
  • 33. Rottenberg M.E., Rothfuchs A.C., Gigliotti D., et al. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J. Immunol 1999; 162:2829.
  • 34. Rottenberg M.E., Rothfuchs A., Gigliotti D., et al. Regulation and role of IFN- in the innate resistance to infection with Chlamydia pneumoniae. J. Immunol 2000; 164:4812.
  • 35. Benjamin W., Starcher B.C., Samten B., et al. Multiple Chlamydia pneumoniae Antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen. J Immunol 2002; 169:2524-35.
  • 36. Yang J., Hooper W.C., Phillips D.J., et al. Induction of proinflammatory cytokines in human lung epithelial cells during Chlamydia pneumoniae Infection. Infect Immun 2003; 71:614-20.
  • 37. Halme S., Latvala J., Karttunen R., et al. Cell-mediated innune response during primary Chlamydia pneumoniae infection. Infect Immun 2000; 68:7156-8.
  • 38. Redecke V., Dalhoff K., Bohnet S., et al. Interaction of Chlamydia pneumoniae and Human Alveolar Macrophages: Infection and Inflammatory Response. Am J Respir Cell Mol Biol 1998; 19:721-7.
  • 39. Peeling R.W., Bailey R.L., Conway D.J., et al. Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma. J Infect Dis 1998; 177:256-9.
  • 40. Peeling R.W., Kimani J., Plummer F., et al. Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease. J Infect Dis 1997; 175:1153-8.
  • 41. Toye B., Laferriere C., Claman P., et al. Association between antibody to the chlamydial heat-shock protein and tubal infertility. J Infect Dis 1993; 168:1236-40.
  • 42. Brunham R.C., Peeling R., Maclean I., Kosseim M.L., Paraskevas M. Chlamydia trachomatis-associated ectopic pregnancy: serologic and histologic correlates. J Infect Dis 1992; 165:1076-81.
  • 43. Huittinen T., Hahn D., Anttila T., et al. Host immune response to Chlamidia pneumoniae heat shock protein 60 is assotiated with asthma. Eur Respir J 2001; 17:1078- 82.
  • 44. Mayr M., Metzler B., Kiechl S., et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamidia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999; 99:1560-6.
  • 45. Huittinen T., Hahn D., Anttila T., et al. Host immune response to Chlamydia pneumoniae heat shock protein 60 is associated with asthma Eur Respir J 2001; 17:1078-82.
  • 46. Kaplan M.A., Goldin M. The use of triacetyloleandomycin in chronic infectious asthma. Jn: Welsh H., MartiIbanez F. eds. Antibiotic annual 1958-1959, Interscience Publishers. 1959. New York, NY: 273-6.
  • 47. Kamada A.K., Hill M.R, Ikle D.N., et al. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993; 91:873-82.
  • 48. Shoji T., Yoshida S., Sakamoto H., et al. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950-6.
  • 49. Amayasu H., Yoshida S., Ebana S., et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 4:594-8.
  • 50. Black P.N., Blasi F., Jenkins C.R., et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care 2001; 164:536-41.
  • 51. Kraft M., Cassell G.H., Pak J., et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in Asthma. Effect of Clarithromycin. Chest 2002;121:1782-8.
  • 52. Ekici A., Ekici M., Erdemoglu A.K. Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma. 2002; 39:181-5.
  • 53. Kostadima E., Tsiodras S., Alexopoulos E.I., et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004; 23:714-7.
  • 54. Hahn D.L., Plane M.B., Mahdi O.S., et al. secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006; 1:e11.
  • 55. Cazzola M., Matera M.G., Blasi F. Macrolide and occult infection in asthma. Curr Opin Pulm Med 2004; 10:7-14.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились